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Abstract
Background. Novel, biocompatible peritoneal dialysis
(PD) solutions have become available in recent years.
In 2001, low glucose degradation products (GDP),
neutral pH solutions became commercially available
in Korea. To date, there are no reports regarding the
large scale adoption of these solutions in clinical
practice and regarding what, if any, impact these
solutions have on patient outcomes.
Methods. Using a database of almost 4000 patients
treated by PD in Korea, we conducted a prospective,
longitudinal observational study documenting the
patterns of use of one novel low GDP solution
(balance, Fresenius Medical Care, St Wendel,
Germany) in 1909 PD incident patients between
1 January 2002 and midyear 2005. Outcomes including
patient and technique survival and peritonitis rates
were analysed using univariate and multivariate
analysis.
Results. Prescription of low GDP solutions reached
between 70 and 80% by the year 2003 and persisted at
this level. Patients prescribed low GDP PD solution
tended to be younger and were more likely to be
treated in centres with larger enrolment in the
database. Survival of diabetic patients treated with
the new PD solution was identical to that of the non-
diabetic patients treated with standard PD fluids
(PDF) and treatment with low GDP PDF indepen-
dently reduced the relative risk (RR) of death
(RR¼ 0.613; CI 0.50–0.74; P< 0.00001) in a propor-
tional hazards model which included age, diabetes and
centre experience. In a univariate analysis, low GDP
PD solution was associated with a longer technique
survival (P¼ 0.049) but this effect was not significant
in multivariate analysis. No significant differences in
peritonitis-free interval or peritonitis rate could be
attributed to the prescribed PDF.
Conclusion. Prescription of low GDP, pH-neutral PD
solutions has rapidly increased in Korea. This change
has resulted in a significant improvement in patient
and technique survival without any measurable change
in peritonitis incidence or rate. Reasons for the
improved patient survival cannot be determined from
this analysis and require further study.
Keywords: CAPD; glucose degradation products;
patient survival; pH neutral; prescribing practices
Introduction
In recent years, novel peritoneal dialysis fluids (PDFs)
with neutral pH and low concentrations of glucose
degradation products (GDP) have become commer-
cially available [1]. GDPs have been established as
major factors in peritoneal fluid bioincompatibility
[2,3] and a large body of experimental evidence from in
vitro and in vivo studies [1–6] and recent clinical results
[7,8] suggest that these novel PDFs provide promise of
improved outcomes for PD patients. In Korea, low
GDP solutions were registered for reimbursement in
July 2001.
In cooperation with the supplier of one such PD
solution [balance provided by (FMCK) Fresenius
Medical Care, Korea], a web-enabled database
was established about this time to monitor PDF
prescription and patient events including patient and
technique survival and peritonitis rates. The results of
our preliminary experience with the novel PDF were
published previously [9]. With more than one year’s
additional experience and a considerably larger
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dataset, we describe here a trend towards preferential
prescription of low GDP PDF and confirm that the
change in the prescription practice is associated with
the superior patient survival.
Patients and methods
The database used for this analysis was described pre-
viously [9]. Briefly, this is a web-enabled database in which
all patients prescribed any continuous ambulatory peritoneal
dialysis (CAPD) or automated peritoneal dialysis (APD)
FMCK are recorded. Patient data were entered by the PD
centre staff assisted as required by the clinical coordinators
employed by FMCK. Recorded data include unique patient
and hospital identifiers, patient age, sex and cause of end-
stage renal disease (ESRD), modality [CAPD, continuous
cycling peritoneal dialysis (CCPD), nocturnal intermittent
peritoneal dialysis (NIPD)], dates for initiation of PD,
change of prescription, ceasing PD and all peritonitis
episodes. Additionally, data are captured for the reasons
for stopping PD and for causes of death and modality
change. Where a patient is converted to a product other than
those provided by FMCK, the product type is recorded but
further events for those patients are not recorded. Also,
further events were not recorded for patients converted to
haemodialysis and for those who received a renal transplant.
On 1 November 2005, the database included 3722
individual patient records. From this, we identified 2317
incident patients between 1 January 2002 and 30 May 2005.
We excluded 43 patients treated by automated PD and 60
juvenile patients (age <18 years) leaving an analysis data
set of 2214 incident CAPD patients. Of these, within the
period of study, 305 patients underwent a change of
prescription—from standard to low GDP PDF. Since the
database did not record reason for prescription preference or
change, these 305 patients were excluded from the final
analysis. As shown in Table 1, the excluded patients were
younger, were more likely to be from more experienced
centres (see subsequently) and had significantly better 1, 2
and 3-year survivals (Kaplan–Meier method) than the 1909
patients included for analysis.
The study close date was set as 30 September 2005. The
patients were treated in 104 PD centres. Of these, 13 centres
that contributed more than 40 patients to the data set
(range 41–193) and accounted for 55% of the total
population were classified as ‘more experienced’ and the
remaining centres as ‘less experienced’.
Statistical analysis
As appropriate, data summaries are provided as means
(and standard deviation), medians (and ranges) or propor-
tions (percentages). Comparisons of treatment groups were
undertaken with standard parametric and non-parametric
tests as appropriate to the data type. Univariate analysis of
survival times was by the Kaplan–Meier life-table method
and significance of differences tested by log rank test.
Multivariate analysis of survival times was undertaken by
Cox proportional hazards modelling with forward stepwise
entry of variables and variable inclusion in the model
determined by the value of the likely ratio statistic.
For each model, proportionality of hazards was tested
by visual observation of the log-minus-log (LML) plots.
All analyses were performed using SPSS version 14.0 (SPSS,
Chicago, IL, USA).
Results
Changing prescription patterns
The new PD solution, balance, was introduced in
Korea mid-year 2001. As shown in Figure 1, the
percentage of initial prescriptions of the low GDP PDF
exceeded 45% of new patients by quarter 1(Q1), 2002.
Within two years, 81% of new patients were prescribed
low GDP PDF in the Q1 of year 2004 and the
prescription preference remained in the range 70–80%
thereafter.
Patient characteristics
As shown in Table 2, 1395 patients were prescribed low
GDP PDF and 514 standard PDF. Patients prescribed
low GDP PDF were younger (56.32 13.42 years)
than patients on standard solution (58.67 14.4;
P¼ 0.001) and included a higher proportion of
patients from more experienced centres (65 vs 56%;
P< 0.0001). Distributions by gender and diabetes
mellitus as the recorded cause of ESRD were similar
in both groups.
Patient outcomes
By the end of the study period, 1119 patients were
alive and being treated with a product provided by
FMCK. The status of all patients on 30 September
2005 according to the prescribed PDF is shown in
Table 3. It is evident that 55% of the deaths were
attributed to cardiac and vascular disease and 8.4% to
sepsis or infection. The proportion of cardiovascular
deaths was higher in patients who prescribed low GDP
PDF (61.5 vs 46.5%) but the difference was not
statistically significant (P¼ 0.387). Similar proportions
Table 1. Selected characteristics of patients included in and excluded
from the final data set for analysis
Included Excluded P-value
Number 1909 305
Prescription Standard 514 –
Low GDP 1395 –
Change – 305
Male/Female 1054/855 161/144 0.429
Diabetic 993 149 0.305
Centre experience Less 710 79 < 0.0001
More 1199 226
Mean age (SD) 56.94
(13.73)
54.34
(13.23)
0.002
Survival 1 year 82% 96% < 0.0001
2 year 71% 89%
3 year 62% 87%
Centre experience categorized according to number of cases included
in the data set: more experience >40 cases.
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from each group received a renal transplant or were
transferred to haemodialysis. Of the 171 patients
converted to haemodialysis (54 from standard PDF
and 117 from low GDP PDF), 49 (29%) transfers were
attributed to peritonitis and 26 (15%) to ultrafiltration
failure; no differences in these proportions were
identified for the prescribed PDF. Of the 57 patients
whose prescription was changed to a product not
provided by FMCK, 31 (54%) were prescribed
icodextrin. The proportions of patients prescribed
icodextrin were similar for both groups (standard
1.2% and low GDP 1.8%; 2¼ 0.918; P¼ 0.338).
Mortality and technique failure rates
The unadjusted mortality rate (expressed per 100
patient years) for patients treated with low GDP
PDF was significantly lower than that of the patients
treated with standard PDF (14.5 vs 29.3; P< 0.0001),
whereas no difference was detected for unadjusted
technique failure rates (low GDP 6.8/100 years;
standard 9.4/100 years; P¼ 0.184).
Patient and PD technique survivals
In univariate analysis (Kaplan–Meier), older age and
diabetes were associated with worse patient survival,
whereas treatment in a more experienced centre and
treatment with low GDP PDF were associated with
improved survival (data not shown). When patients
were stratified according to diabetic status, the use of
low GDP PDF was associated with superior survival
for diabetic and non-diabetic patients (all P-values
<0.0001). Moreover, the survival plot for diabetic
patients treated with low GDP PDF was identical to
that for non-diabetic patients treated with standard
PDF (P¼ 0.913: Figure 2).
In a multivariable Cox proportional hazards
model which included patient sex, age, diabetic
status, centre experience, history of peritonitis (any vs
none), prescribed PDF and the interaction between
prescribed PDF and centre experience, there was an
independent and significant reduction in hazard of
death (relative risk) associated with the use of low
GDP PDF. As expected, older age and diabetes were
associated with increased relative risk of death and
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Fig. 1. Changing proportion of patients prescribed standard and low GDP peritoneal dialysis fluids (PDF) over the period of the study—
January 2002–May 2005.
Table 2. Selected characteristics of patients according to the
prescribed PD solution
Prescribed PD Solution
Standard Low GDP P-value
Number 514 1395
Male/female 301/213 753/642 0.074
Diabetic 273 720 0.298
Centre experience Less 224 486 < 0.0001
More 290 909
Mean age (SD) 58.67
(14.40)
56.32
(13.42)
0.001
Centre experience categorized according to number of cases included
in the data set: more experience >40 cases.
Table 3. Status of all patients on 1 October 2005 (at the end of the
study)
Prescribed PDF
Standard Low GDP
n % n %
Alive 223 43.4 896 64.2
Dead 176 34.2 265 19.0
To haemodialysis 54 10.5 117 8.4
To renal transplant 30 5.8 59 4.2
To other product 19 3.7 38 2.7
Recovered renal function 10 1.9 13 0.9
Other/unknown 2 0.4 7 0.5
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death risk was significantly reduced for patients treated
in more experienced PD centres. There was no
significant interaction for PDF and centre experience
(Table 4 and Figure 3).
PD technique survival was analysed in a similar
manner to patient survival. The measured event was
treated in two ways. In the first method, the event was
the time to conversion to haemodialysis with deaths
and renal transplants censored. In the second method,
the event was defined as death or conversion to
haemodialysis and renal transplants were censored.
For the first method of analysis in univariate analysis
by Kaplan–Meier prescription low GDP PDF was
associated with a longer technique survival (at 3 years
84 vs 77% for standard PDF; P¼ 0.049), but this
difference was not retained in a Cox multivariable
model (same variables as aforementioned) where only
centre experience (more vs less) was found to be
independently predictive of better technique survival.
In the second method of analysis, effectively an
analysis of ‘PD success’, in both univariate (Kaplan–
Meier) and multivariable (Cox proportional hazards)
analyses, significantly longer PD technique survival
was identified for patients treated with the low GDP
solution. The results are shown in Table 5 and Figure 4
where the survival plots represent the survivals at
the mean of all variables included in the model.
As shown in Figure 4, the prescription of low GDP
solution prolonged the technique survival by more
than 1 year compared with the prescription of standard
solution. In an additional model where the conversion
of the patients’ prescription to icodextrin (as indicating
a failure of standard PD therapy) was included
as a technique failure, the results of univariate and
multivariable technique survival analysis were essen-
tially unchanged (data not shown).
Peritonitis rates and peritonitis-free survival
Of the 1909 patients, 460 (24%) suffered at least
one peritonitis event. The peritonitis rates were
0.29 per year (1 per 41 months) for standard PDF
and 0.26 per year (1 per 46 months) for low GDP PDF
(P¼ 0.479). There was no difference in peritonitis-free
interval (Kaplan–Meier method) for the two PD
solutions.
Table 4. Multivariable Cox proportional hazards model for time to death
Confidence interval
RR Lower Upper P-value
PD solution (Low GDP vs standard) 0.613 0.504 0.744 0.00000
Age (per year older) 1.062 1.052 1.071 0.00000
Diabetes (yes vs no) 1.690 1.378 2.072 0.00008
Centre experience (more vs less) 0.678 0.559 0.823 0.00000
Variables entered: age, diabetes, centre experience, peritonitis (any vs none), year enrolment, PD solution, interaction between PD solution
and centre experience: RR, relative risk of death. Centre experience categorized according to number of cases included in the dataset: more
experience >40 cases.
Fig. 3. Plots of patient survival at the mean of all included variables
(covariates) in the Cox proportional hazards model comparing
patients treated with standard and low GDP PD solutions. Details
provided in Table 4.
Fig. 2. Plots of probability of patient survival by univariate analysis
(Kaplan–Meier method) by diabetic status and prescribed PD
solution (standard PDF and low GDP PDF).
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Discussion
We describe here a rapid change in PDF prescription
practice in over 1900 incident CAPD patients in Korea
treated during the period 2002 through midyear 2005.
Patients prescribed low GDP PDF were younger than
those prescribed standard PDF (Tables 1 and 2) and
centres with more patients enrolled in the database
appeared more likely to prescribe the low GDP PDF.
Thus, patient age and a ‘centre effect’ probably
contribute to the results we describe, but the benefit
of low GDP prescription on patient survival retained
independence and significance in a multivariable
survival analysis that included both variables.
In this population, 76% of the patients never
experienced peritonitis which is the same proportion
reported as peritonitis-free by Kim et al. [10] from
the Korean Renal Registry. The peritonitis rate of
our patients was low (<0.3 episodes per year) but we
could not identify any effect of low GDP PDF in
reducing peritonitis rate or prolongation of the
peritonitis-free interval.
We cannot categorically state that there was no
negative selection of the patients prescribed and
maintained on standard PDF. Kim et al. [10], reporting
for the Korean ESRD registry, described a combined
patient and technique survival rate for Korean CAPD
patients of 31.9% at 3 years. It is likely that almost
all of those patients were treated with standard PDF.
In a combined technique and patient survival, using
Kaplan–Meier analysis and where technique failure
was defined as conversion to haemodialysis, we found
a 3 year survival of 34% of the patients treated with
standard PDF (data not shown), similar to the total
survival reported by Kim et al. [10]. This finding argues
against significant negative selection of our patients
treated with standard PDF.
On the other hand, was there a positive selection of
a lower risk group for prescription of the low GDP
PDF? These patients were younger by 2.4 years on
an average, but included a similar proportion of
diabetic patients. Based on an upper bound for the
effect of age on survival (7.1% increased risk of death
for each additional year age), younger age might have
accounted for 18% (less than half) of the 39%
reduced risk of death associated with the prescription
of low GDP PD solution.
Those centres with more patients included in this
data set and thereby defined as more experienced were
more likely to prescribe the low GDP PDF, and both
by univariate and multivariable analysis, experienced
superior technique and patient survival than less-
experienced centres. However, in multivariable analy-
sis, the effect of the PDF on patient and technique
survival remained robust and independent of the
centre effect.
Two approaches are used to define technique failure
(or success) in PD. In one, modality conversion to
haemodialysis is the measured event and deaths are
censored, whereas in the other, deaths and conversions
to haemodilaysis are the events. Using the latter
method, our analysis indicates significantly superior
technique survival for low GDP solution in univariate
and multivariable analysis, whereas using the former
method, a significantly improved technique survival
for low GDP solution detected in Kaplan–Meier
analysis failed to retain significance in multivariable
analysis where centre experience was the solitary factor
of significance.
A significant contributing cause to PD technique
failure is membrane failure for ultrafiltration—
ultrafiltration failure (UFF). One therapeutic alter-
native for treating UFF is recourse to prescription of
icodextrin. Thus, the requirement for prescription
of icodextrin might be considered a ‘failure’ of
standard PD. We detected no difference in the rates
of prescription of icodextrin (low GDP PDF 1.8% and
standard PDF 1.2%), and in an analysis that extended
the definition of technique failure to include patient
Fig. 4. Plots of PD technique survival (cases censored at conversion
to haemodialysis) at the mean of all included variables (covariates) in
the Cox proportional hazards model comparing patients treated with
standard and low GDP PD solutions. Details provided in Table 5.
Patients treated with low GDP PDF have a technique survival  1.4
years greater than those prescribed standard PDF.
Table 5. Multivariable Cox proportional hazards model for time to
technique failure (method 2: see text)
Confidence interval
RR Lower Upper P-value
PD solution (Low GDP
vs standard)
0.638 0.540 0.753 0.00000
Age (per year older) 1.040 1.033 1.047 0.00000
Diabetes (yes vs no) 1.461 1.234 1.730 0.00001
Centre experience (more vs less) 0.625 0.531 0.736 0.00000
Variables entered: age, diabetes, centre experience, peritonitis (any vs
none), year enrolment, PD solution, interaction between PD solution
and centre experience: RR, relative risk of death. Centre experience
categorized according to number of cases included in the data set:
more experience >40 cases.
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prescription of icodextrin, the technique survival
analysis by univariate and multivariable analysis was
not significantly changed (data not shown).
Because of the limitations imposed by the design of
the database, we cannot identify a mechanism for the
improved survival imparted by the prescription of the
low GDP solution.
Recent reports from mainly observational data have
identified various associations for higher mortality in
PD patients including impaired nutrition, systemic
inflammation and, probably most dominantly, loss of
residual renal function [11–13]. In the Euro-Balance
Trial, Williams et al. [8] noted better preservation
of residual renal function in a cross-over study of
balance and standard PDF and reported preliminary
results of the DIUREST study. Haag-Weber et al. [14]
described better preservation of residual renal func-
tion for patients treated with another low GDP
solution (Gambro Trio) compared with patients on
standard PDF [14]. We are aware of an ongoing
randomized controlled trial that is specifically examin-
ing the possible effect of low GDP PDF on the rate
of change in residual renal function [15]. Hopefully,
this study (results expected in 2008) will clarify this
critically important question.
Of particular interest was the effect of low GDP
PDF on the survival of diabetic patients who
accounted for 51% of this cohort. In effect, the
probability of survival of diabetic patients treated
with low GDP PDF was the same as that of non-
diabetic patients treated with the standard PDF
(Figure 2). A possible and testable hypothesis for the
survival advantage associated with low GDP PD
solution prescription might relate to advanced glyca-
tion. In the Euro-Balance Trial, Williams et al. [8]
reported significant lowering of serum levels of the
advanced glycation end-products (AGE), carboxy-
methyllysine and imidazolone, in patients treated for
3 months with the low GDP solution, balance, when
compared with the AGE levels on standard PDF.
Greater and more sustained reduction in circulating
AGE levels might be expected in our patients who were
treated for up to 3½ years with low GDP PDF.
Advanced glycation has been implicated in the causa-
tion of microvascular and macrovascular disease in
diabetics and in age-related kidney disease.
Furthermore, absorption of GDPs from the perito-
neum may promote systemic advanced glycation
[16,17]. AGE–AGE receptor (RAGE) binding induces
transcription for increased production of inflammatory
cytokines, adhesion molecules, growth and pro-fibrotic
factors from monocytes, endothelial cells and mesothe-
lial cells [18]. AGE have been implicated in chronic
allograft nephropathy, a model of progressive loss
of renal function [19] and reduction of circulating
AGE by dietary manipulation protects the kidney
function in the aging rat [20]. Thus, it is plausible that
reduction in systemic AGE levels exerts a protective
effect on native renal function, thereby improving
patient survival. This hypothesis should be tested in an
appropriately designed clinical study.
Conclusion
We report a major increase in the prescription of low
GDP PDF in a large cohort of incident CAPD patients
in Korea following their commercial introduction in
our country. As yet, we have not been able to identify
factors determining prescription choice. This change in
PD prescription practice has resulted in a significant
improvement in patient outcomes.
These results need to be confirmed in other nations
by appropriately designed studies.
Given that prescribing nephrologists might be
reluctant to undertake wholesale prescription of these
new solutions on the evidence now available, our data
suggest that the diabetic CAPD candidate might be
a preferred target for an early adoption.
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